Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
A new study may offer a strategy that mitigates negative side effects associated with intravenous injection of nanoparticles commonly used in medicine. The study was published today in Nature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results